The role of investor relations (IR) is to keep shareholders and investors informed so that they can make investment decisions with confidence. Through that, the value of the company can then be evaluated appropriately. When challenging situations arise, its true merit is put to the test.
Successfully navigating an unprecedented acquisition with Integrity at heart.
Having previously worked in accounting, internal control system creation, and public relations (PR), I joined the IR team five years ago. Through my personal experience of working in these positions, I have developed a deep understanding of Takeda’s dynamic, global corporate activities.
For example, while I was working in PR, Takeda changed direction quite significantly, moving to a strategy of integrating growth areas from around the world with the acquisition of the U.S. firm Millennium Pharmaceuticals in 2008, and the Swiss-based company Nycomed in 2011. In 2014, Christophe Weber, who had been working for GSK, was appointed President, and then finally, in 2019, Takeda acquired Shire, a world leader in the field of rare diseases, for more than 6 trillion yen ($56 billion).
That acquisition was completed as a combination of a cash payment as well as a share exchange in the form of the issuing of new shares, a method that was more or less unprecedented.